Journals / Bezmiâlem Science / 2020 / Cilt: 8 - Sayı: 3

SARS CoV-2 Pathogenesis and Immune Response

The agent responsible for the epidemic that first appeared in Wuhan, China, in December 2019 was detected to be the new coronavirus (2019-nCoV). Later, the virus that caused respiratory tract infection was discovered to be a member of the beta-cor

Pages
98–101
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review presents an overview of SARS-CoV2 andaims to examine its intracellular pathogenesis and host immuneresponses.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The agent responsible for the epidemic that first appeared in Wuhan,China, in December 2019 was detected to be the new coronavirus(2019-nCoV).
📊
Key Findings & Data:Later, the virus that caused respiratory tract infectionwas discovered to be a member of the beta-coronavirus family, itwas named as severe acute respiratory syndrome-CoV2 (SARS-CoV2), and the disease it caused was called CoV infection disease-19(COVID-19).
💡
Conclusion & Impact:This review presents an overview of SARS-CoV2 andaims to examine its intracellular pathogenesis and host immuneresponses.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

The agent responsible for the epidemic that first appeared in Wuhan,China, in December 2019 was detected to be the new coronavirus(2019-nCoV). Later, the virus that caused respiratory tract infectionwas discovered to be a member of the beta-coronavirus family, itwas named as severe acute respiratory syndrome-CoV2 (SARS-CoV2), and the disease it caused was called CoV infection disease-19(COVID-19). The epidemic started in China, spread rapidly firstto East Asian countries, then Europe and America, affected thewhole world, and was declared a pandemic by the World HealthOrganization. This review presents an overview of SARS-CoV2 andaims to examine its intracellular pathogenesis and host immuneresponses.

Özet

İlk kez Çin’in Wuhan kentinde Aralık 2019’da ortaya çıkansalgından sorumlu olan etkenin yeni koronavirüs (2019-nCoV)olduğu saptanmıştır. Daha sonra, solunum yolu enfeksiyonuna yolaçan bu virüsün beta-CoV ailesine ait olduğu belirlenip, şiddetli akutsolunum yolu enfeksiyonu-koronavirüs-2 (SARS-CoV-2) olarakadlandırılmış ve oluşturduğu hastalığa da koronavirüs enfeksiyonhastalığı-19 (COVİD-19) denilmiştir. Çin’de başlayan salgın hızlaDoğu Asya ülkelerine sonrasında Avrupa ve Amerika’ya yayılarak,tüm dünyayı etkisi altına almış ve Dünya Sağlık Örgütü tarafındanpandemi olarak ilan edilmiştir. Bu derleme, bu virüsle ilgili genel birbakış açısı sunmakla birlikte, hücre içindeki patogenezini ve konakimmün yanıtlarını incelemeyi amaçlamıştır.

🔖

Cite This Article

DİNÇ, H. Ö., MAYDA, P. Y. (2022). SARS CoV-2 Pathogenesis and Immune Response. Bezmiâlem Science, Cilt: 8 - Sayı: 3, 98–101. https://ajindex.com/articles/464085

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24:490-502
  2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3
  3. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74
  4. World Health Organization. (2020). https://www.who.int/dg/ speeches/detail/who-director-general-s-opening-remarks-at-themission-briefing-on-covid-19---12-march-2020
  5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. doi: 10.1056/NEJMoa2002032. [Epub ahead of print] 6. World Health Organization, Coronavirus disease (COVID-19) pandemic. (2020). Last Accessed Date: 30.06.2020 Available from:
  6. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91-8
  7. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. New York: Springer; 2015:1-23
  8. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92
  9. Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011;85:4122-34
  10. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S. TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein. J Virol 2014;88:1293-307
  11. Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher TA. Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry J Virol 2011;85:873-82
  12. Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr 2020;14:407-12
  13. Lauer SA, Grantz KH, B